Open AccessDrospirenone/Ethinyl EstradiolVersusRosiglitazone Treatment in Overweight Adolescents with Polycystic Ovary Syndrome: Comparison of Metabolic, Hormonal, and Cardiovascular Risk Factors
Author(s) -
Hala Tfayli,
Julia Warren Ulnach,
SoJung Lee,
Kim SuttonTyrrell,
Silva Arslanian
Publication year - 2011
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2010-2547
Subject(s) - drospirenone , polycystic ovary , medicine , rosiglitazone , overweight , endocrinology , metabolic syndrome , hormone , obesity , insulin resistance , insulin
Adolescents with polycystic ovary syndrome (PCOS) have insulin resistance and higher rates of the metabolic syndrome.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom